This study is testing a medication called tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease (COPD). Tezepelumab is given as an injection under the skin. Some participants will receive tezepelumab, while others will receive a placebo (an inactive injection that looks like the study drug). The main goal is to see if tezepelumab can reduce the number of moderate or severe COPD flare-ups (exacerbations) over about 76 weeks, and to check its safety. You may be able to join if you are between 40 and 80 years old, have had COPD for at least a year, and have experienced at least two moderate or one severe COPD flare-up in the past year. The study is currently recruiting about 990 participants.

Study design

This is a Phase 3, randomized, double-blind study, meaning neither you nor your doctor will know if you are receiving tezepelumab or a placebo. The study plans to enroll about 990 participants.

What's involved

Participants will receive monthly subcutaneous injections of tezepelumab or placebo for a minimum of 52 weeks and a maximum of 76 weeks.

Compensation

Not stated in the trial record.

Follow-up

After the treatment period, there will be a safety follow-up period of 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.